1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. North America Glycomic Therapeutics Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. North America Glycomic Therapeutics Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. North America Glycomic Therapeutics Market Regional Analysis
6.2 North America Glycomic Therapeutics Market Revenue 2020-2028 (US$ Million)
6.3 North America Glycomic Therapeutics Market Forecast Analysis
7. North America Glycomic Therapeutics Market Analysis – by Class
7.1 Isolated and Synthetic
- 7.1.1 Overview
- 7.1.2 Isolated and Synthetic: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
8. North America Glycomic Therapeutics Market Analysis – by Structures
8.1 Glycoproteins
- 8.1.1 Overview
- 8.1.2 Glycoproteins: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
8.2 Targeting Sialic Acid
- 8.2.1 Overview
- 8.2.2 Targeting Sialic Acid: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
8.3 Proteoglycans
- 8.3.1 Overview
- 8.3.2 Proteoglycans: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
8.4 Targeting Glycosaminoglycans
- 8.4.1 Overview
- 8.4.2 Targeting Glycosaminoglycans: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
8.5 Glycosylphosphatidylinositol-Anchored Proteins & Heparin Based Glycans
- 8.5.1 Overview
- 8.5.2 Glycosylphosphatidylinositol-Anchored Proteins & Heparin Based Glycans: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
8.6 Targeting Glycosphingolipids
- 8.6.1 Overview
- 8.6.2 Targeting Glycosphingolipids: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
9. North America Glycomic Therapeutics Market Analysis – by Indications
9.1 Thrombosis & Chemoprophylaxis
- 9.1.1 Overview
- 9.1.2 Thrombosis & Chemoprophylaxis: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
9.2 Anaemia
- 9.2.1 Overview
- 9.2.2 Anaemia: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
9.3 Anti-Adhesive & Anti-Inflammatory
- 9.3.1 Overview
- 9.3.2 Anti-Adhesive & Anti-Inflammatory: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
9.4 Cataracts
- 9.4.1 Overview
- 9.4.2 Cataracts: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
9.5 Gaucher's Disease
- 9.5.1 Overview
- 9.5.2 Gaucher's Disease: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
9.6 MPS-1 & IV
- 9.6.1 Overview
- 9.6.2 MPS-1 & IV: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
9.7 Cancer
- 9.7.1 Overview
- 9.7.2 Cancer: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
9.8 Alzheimer's Disease
- 9.8.1 Overview
- 9.8.2 Alzheimer's Disease: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
9.9 Influenza Type A & B
- 9.9.1 Overview
- 9.9.2 Influenza Type A & B: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
10. North America Glycomic Therapeutics Market Analysis – by Mode of Action
10.1 Inhibits Neuraminidase
- 10.1.1 Overview
- 10.1.2 Inhibits Neuraminidase: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
10.2 Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate
- 10.2.1 Overview
- 10.2.2 Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
10.3 Erythropoietin & Enzyme Replacement Therapy
- 10.3.1 Overview
- 10.3.2 Erythropoietin & Enzyme Replacement Therapy: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
10.4 Tissue Plasminogen Activator
- 10.4.1 Overview
- 10.4.2 Tissue Plasminogen Activator: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
10.5 Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3
- 10.5.1 Overview
- 10.5.2 Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
10.6 Beta & Gamma Interferons
- 10.6.1 Overview
- 10.6.2 Beta & Gamma Interferons: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
10.7 Others
- 10.7.1 Overview
- 10.7.2 Others: North America Glycomic Therapeutics Market – Revenue and Forecast, 2020-2028 (US$ Million)
11. North America Glycomic Therapeutics Market – North America Analysis
11.1 Overview
11.2 North America
- 11.2.1 North America Glycomic Therapeutics Market Breakdown, by Key
Country, 2023 and 2028 (%)
- 11.2.1.1 North America Glycomic Therapeutics Market – Revenue and
Forecast Analysis – by Country
- 11.2.1.1 US:
North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.1.1 US: North America Glycomic Therapeutics Market Breakdown, by Class
- 11.2.1.1.2 US: North America Glycomic Therapeutics Market Breakdown, by Structures
- 11.2.1.1.3 US: North America Glycomic Therapeutics Market Breakdown, by Indications
- 11.2.1.1.4 US: North America Glycomic Therapeutics Market Breakdown, by Mode of Action
- 11.2.1.2 Canada:
North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.2.1 Canada: North America Glycomic Therapeutics Market Breakdown, by Class
- 11.2.1.2.2 Canada: North America Glycomic Therapeutics Market Breakdown, by Structures
- 11.2.1.2.3 Canada: North America Glycomic Therapeutics Market Breakdown, by Indications
- 11.2.1.2.4 Canada: North America Glycomic Therapeutics Market Breakdown, by Mode of Action
- 11.2.1.3 Mexico :
North America Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.3.1 Mexico : North America Glycomic Therapeutics Market Breakdown, by Class
- 11.2.1.3.2 Mexico : North America Glycomic Therapeutics Market Breakdown, by Structures
- 11.2.1.3.3 Mexico : North America Glycomic Therapeutics Market Breakdown, by Indications
- 11.2.1.3.4 Mexico : North America Glycomic Therapeutics Market Breakdown, by Mode of Action
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 BioMarin Pharmaceutical Inc.
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Genzyme Corporation (Sanofi)
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Halozyme Therapeutics, Inc.
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Bayer AG
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Alzheon, Inc.
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 GlycoMar
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 GlaxoSmithKline plc.
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 F.Hoffmann-La Roche Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations